Page last updated: 2024-11-04

sb 239063 and Pneumonia

sb 239063 has been researched along with Pneumonia in 1 studies

SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.

Pneumonia: Infection of the lung often accompanied by inflammation.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smith, SJ1
Fenwick, PS1
Nicholson, AG1
Kirschenbaum, F1
Finney-Hayward, TK1
Higgins, LS1
Giembycz, MA1
Barnes, PJ1
Donnelly, LE1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Regulation of the Release of Inflammatory Mediators From Lung Macrophages.[NCT00147017]17 participants (Actual)Observational2001-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Interleukin, IL-8

(NCT00147017)
Timeframe: 20 hours

Interventionng/ml (Mean)
Smokers220.8
Ex-smokers251.2
Emphysema Lung Transplant167.8

Macrophage Activation, GM-CSF

GM-CSF, granulocyte macrophage-colony stimulating factor (NCT00147017)
Timeframe: 20 hours

Interventionng/ml (Mean)
Smokers2.2
Ex-smokers1.8
Emphysema Lung Transplant2.6

Macrophage Activation, TNF-a

measure release of inflammatory mediators from isolated macrophages (NCT00147017)
Timeframe: 20 hours

Interventionng/ml (Mean)
Smokers6.1
Ex-smokers3.8
Emphysema Lung Transplant2.6

Other Studies

1 other study available for sb 239063 and Pneumonia

ArticleYear
Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.
    British journal of pharmacology, 2006, Volume: 149, Issue:4

    Topics: Blotting, Western; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Female; Granulocyte

2006